| Name | Cefuroxime sodium |
| Description | Cefuroxime Sodium is the sodium salt form of cefuroxime and a semi-synthetic, broad-spectrum, beta-lactamase resistant, second-generation cephalosporin antibiotic with bactericidal activity. Cefuroxime sodium (Cefuroxime sodium salt) inhibits bacterial cell wall synthesis by inactivating penicillin binding proteins (PBPs) thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of the cell wall. Lack of cross-linking results in a reduction of cell wall stability and leads to cell lysis. |
| In vivo | The intravenous LD50 of cefuroxime sodium for mice is 10.4 g/kg. The maximum dosage administered in other acute toxicity tests is well tolerated by mice (10 g/kg, subcutaneous), by rats (4 g/kg, intravenous, 5 g/kg, subcutaneous) and by cats, dogs and monkeys (2 g/kg, intramuscularly). However, when cefuroxime sodium is administered subcutaneously (s.c.) or intramuscularly (i.m.) for 3 months to rats (100, 300 or 900 mg/kg/day) followed by a recovery period, and also for 6 months to rats and dogs (50, 150 or 450 mg/kg/day) and for 1 month to monkeys (150 or 450 mg/kg/day), there are no serious toxic effects in all tests. In rats large doses cause some increase in urine volume and electrolyte excretion, and slightly aggravates an age related nephropathy. Administration to rats intravenously (i.v.) for 1 month of up to 400 mg/kg/day has no toxic effects. In reproduction studies on mice and rabbits there are no adverse effects on fertility, organogenesis or the rearing of young[1]. |
| Storage | 02 | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.48 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 250 mg/mL (560.07 mM), Sonication is recommended.
|
| Keywords | β-lactamase | Streptococcus pyogenes | S. faecalis | Cefuroxime sodium | Cefuroxime | Bacterial | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | Drug-induced Liver Injury (DILI) Compound Library | ReFRAME Related Library | Toxic Compound Library | Drug Repurposing Compound Library | Anti-Bacterial Compound Library | FDA-Approved Drug Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | NMPA-Approved Drug Library |
United States
